Skip to main content
Zhejiang Xinguang Pharmaceutical Co., Ltd. logo

Zhejiang Xinguang Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300519 ISIN · CNE1000027T3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 841 across all filing types
Latest filing 2026-05-21 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 300519

About Zhejiang Xinguang Pharmaceutical Co., Ltd.

https://www.xgpharma.com

Zhejiang Xinguang Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of pharmaceutical products, with a primary focus on modern Chinese patent medicines. The company’s portfolio includes a diverse range of formulations such as oral liquids, capsules, tablets, and granules. Its flagship product, Huangqi Shengmai Drinking Liquid, is widely recognized for its applications in cardiovascular health and immune system support. The company integrates traditional Chinese medicine principles with modern pharmaceutical technology to address various therapeutic areas, including cardiovascular diseases, digestive disorders, and respiratory conditions. By maintaining rigorous quality control standards and investing in advanced production facilities, the company aims to provide effective healthcare solutions. Its operations encompass the entire value chain from raw material sourcing to clinical research and market distribution.

Recent filings

Filing Released Lang Actions
2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is a formal announcement detailing the annual profit distribution plan (cash dividends per 10 shares), record date, ex-dividend date, tax arrangements, and payment logistics. It’s clearly a dividend distribution notice rather than a full report or proxy statement. Therefore, it fits the “Notice of Dividend Amount” category.
2026-05-21 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence - The document title is “2025年年度股东会决议公告,” indicating it is an announcement of the resolutions passed at the 2025 Annual Shareholders’ Meeting. - The text details meeting attendance, voting methods (onsite and online), and precise vote counts and percentages for each agenda item. - It provides the official voting results for proposals made at the AGM, matching the definition of Declaration of Voting Results & Voting Rights Announcements. - Therefore, this document should be classified as DVA.
2026-05-15 Chinese
上海市锦天城律师事务所关于新光药业2025年年度股东会的法律意见书
Regulatory Filings Classification · 88% confidence The document is a standalone lawyer’s legal opinion (“法律意见书”) issued by a law firm on the legality of convening and conducting the 2025 Annual Shareholders’ Meeting, including verification of procedures and vote counts. It is not the meeting minutes or a presentation of AGM materials, nor a pure announcement of vote results by the company. Rather, it is a compliance certification letter. Under the Classification Rules, such an officer certification/legal opinion should be classified as a general Regulatory Filing (RNS).
2026-05-15 Chinese
关于公司持股5%以上股东股份减持计划的预披露公告
Major Shareholding Notification Classification · 95% confidence The document is a formal announcement by a shareholder holding over 5% of the company’s shares regarding its planned reduction of up to 3% of total share capital. It does not involve a report of company financial results, AGM materials, or regulatory certification. It is not a company share buyback (POS) nor a board change (MANG). Instead, it is a notification by a major shareholder of intended shareholding changes, fitting the Major Shareholding Notification category (MRQ).
2026-05-12 Chinese
关于召开公司2025年年度股东会的提示性公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice of the company’s 2025 Annual General Meeting, including meeting date, agenda items, voting methods, proxy forms, registration procedures, and attachments (proxy authorization form, shareholder registration form, voting process). It is not the actual AGM materials (presentations/slides) nor a results announcement, but a solicitation/information statement to shareholders for voting at the meeting. This aligns with the definition of a Proxy Solicitation & Information Statement (PSI).
2026-05-11 Chinese
2025年度新光药业募集资金存放与使用情况专项报告
Capital/Financing Update Classification · 72% confidence The document is a standalone “专项报告” on the company’s募集资金 (funds raised) deposit, management, and usage for the 2025 fiscal year, prepared under the Listing Company Raised Funds Supervision Rules and exchange self-regulatory guidelines. It is not an annual/interim report or earnings release, nor a meeting presentation or voting result notice. It provides a detailed update on the status and deployment of the capital raised, which corresponds to a capital/financing update. Therefore, it best fits the Capital/Financing Update category (CAP).
2026-04-20 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.